Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $13.69 and traded as high as $18.50. Assembly Biosciences shares last traded at $18.45, with a volume of 21,313 shares changing hands.
Assembly Biosciences Stock Performance
The stock has a market capitalization of $141.72 million, a price-to-earnings ratio of -2.98 and a beta of 0.62. The company's 50 day moving average is $16.86 and its 200 day moving average is $13.70.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.01) by $0.84. Assembly Biosciences had a negative net margin of 124.15% and a negative return on equity of 131.77%. The company had revenue of $9.42 million during the quarter, compared to analysts' expectations of $7.41 million. On average, equities research analysts anticipate that Assembly Biosciences, Inc. will post -6.87 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Assembly Biosciences
Hedge funds have recently made changes to their positions in the company. Gilead Sciences Inc. acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth about $34,865,000. Renaissance Technologies LLC grew its position in shares of Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock worth $1,495,000 after buying an additional 29,087 shares during the period. Man Group plc bought a new stake in Assembly Biosciences in the fourth quarter valued at approximately $309,000. JPMorgan Chase & Co. increased its stake in Assembly Biosciences by 225.6% in the fourth quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock valued at $180,000 after purchasing an additional 7,918 shares in the last quarter. Finally, B Group Inc. acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $799,000. Institutional investors and hedge funds own 19.92% of the company's stock.
Assembly Biosciences Company Profile
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Recommended Stories
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
